Dr. Drutz' career spans 36 years in clinical medicine and patient care, basic and clinical research, pharmaceutical and biotechnology operational and research management and venture capital. Dr. Drutz received his M.D. degree at the University of Louisville, and postgraduate medical training at Vanderbilt University, following which he served as a U.S. Navy medical officer in Asia. He held senior faculty positions at the University of California, San Francisco, University of Texas and the University of Pennsylvania. He is board-certified in Internal Medicine and a Fellow of the American College of Physicians and the Infectious Diseases Society of America. Dr. Drutz currently serves as Chairman of the board of directors for Gentris and Vaxin, Inc. and as a director of MethylGene Inc. (TSX: MYG), a biopharmaceutical company. From 2000 to 2010, Dr. Drutz served as Chairman of the board of directors of Tranzyme Pharma, Inc. He was a General Partner with Pacific Rim Ventures (PRV), a global biotechnology investment company from 1999 to 2010. He has also been President of Pacific Biopharma Associates, a biotechnology consulting firm, since 1999. Dr. Drutz was formerly Vice President Biological Sciences (Drug Discovery) and Vice President Clinical Research (AIDS therapeutics) at Smith Kline and French Laboratories in King of Prussia, PA, and Vice President Clinical Development, Daiichi Pharmaceutical Corporation, Ft. Lee, NJ. At Daiichi he was responsible for the development of five anti-infective and oncology products. Dr. Drutz left Daiichi in 1990 to enter the biotechnology industry. Before joining PRV he was President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH), a company specializing in therapeutics for diseases of the respiratory tract and other mucus membrane surfaces. Dr. Drutz' experience as a medical doctor board-certified in Internal Medicine is extremely valuable to our board. In addition to his medical background, Dr. Dr

Mr. Clement has a 30 year career in the biopharmaceutical industry that includes executive management, marketing and sales, strategic and product planning, business development, and general management. Prior to joining DARA, Mr. Clement served as the President Chief Executive Officer, and Board member of Oncogenerix, a privately held specialty bio pharmaceutical company focused on the identification, development and commercialization of oncological bio-pharmaceutical products. From 2002 to 2009, he was the President and Chief Executive Officer of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), a publicly traded specialty pharmaceutical company where he was successful in divesting non-core assets, developing KRYSTEXXA (peg-uricase), through pivotal phase III clinical trials and filing a BLA with the FDA. Mr. Clement’s experience in executive and senior management positions include: Ares-Serono Group, a Swiss developer of pharmaceuticals; Searle Pharmaceuticals – a research-based pharmaceutical company that manufactures and markets prescription pharmaceuticals and other healthcare solutions worldwide; and Epicyte Pharma, a pharmaceutical company engaged in the development of antibody-based products. Mr. Clement received a B.A. in Marketing and Business from Mercy College.

Mr. Cochrane served as Vice Chairman and a director of I-Trax, Inc. (AMEX: DMX), a publicly traded, total population health management and productivity company, from 2004 to 2008. He joined I-Trax when I-Trax acquired CHD Meridian Healthcare where he served as Chairman and Chief Executive Officer from 1997 to 2004. Mr. Cochrane has over 20 years of healthcare experience in executive and senior management positions, including Senior Vice President and Chief Operating Officer of Roche Biomedical Laboratories, President and Chief Executive Officer of Allied Clinical Laboratories and Executive Vice President and Chief Financial Officer of Laboratory Corporation of America. Mr. Cochrane earned an A.B. degree in Political Science from the University of North Carolina at Chapel Hill where he was a Morehead Scholar. Mr. Cochrane brings to our board extensive executive and senior management experience in the healthcare industry and is an “audit committee financial expert” as such term is defined under applicable SEC rules. He is further qualified for service on our board because of his relevant business expertise and leadership experience acquired through his experience serving as Vice Chairman and Chairman of the boards of directors of other healthcare-related companies.

Ms. Lieberman currently serves as director on the audit committee of ICTS International N.V. Ms. Lieberman is the founder and Managing Partner of Rudder Capital, LLC, which provides financial and strategic advisory services for middle-market companies including M&A advisory and strategic consulting. She has been a Chief Financial Officer for several Fortune 500 companies, including Thomson Corporation’s Financial & Professional Publishing division, Moody’s Investor Service (D&B) and Scali, McCabe, Sloves (Ogilvy Group). Ms. Lieberman has recently served as a Director for three public companies in the healthcare and aerospace sectors: I-Trax Inc. (Amex: DMX); TriPath Imaging Inc. (NASDQ: TPTH); and Breeze-Eastern Corporation (Amex: BZC). In addition, she sits on several advisory boards and non-profit boards including NY Report and Urban Glass. Ms. Lieberman holds a BA in Mathematics and Physics and an MBA in Finance from Temple University. Ms. Lieberman has a significant understanding of the role played by the board of directors which was acquired through her service on the boards of several companies, including public companies in the healthcare and aerospace industries. She provides the board with financial expertise acquired through experience as the CFO of several Fortune 500 companies and as the founder and managing partner of a financial and strategic advisory consulting firm. Ms. Lieberman’s educational background in Math, Physics and Business Administration also provides our board with a unique and valuable perspective.

Mr. Thomas serves as the Chief Financial Officer of Motion Reality, Inc., a privately-held simulation company and CorMatrix Cardiovascular, Inc., a privately-held medical device company. Mr. Thomas served as the Chief Financial Officer of DARA from 2002 – 2009. Other companies for which he has served as the Chief Financial Officer include: MiMedx Group, Inc; SurgiVision, Inc.; GMP Companies, Inc.; EntreMed, Inc.; Medicis Pharmaceutical Corporation; Biopool International, Inc.; and CytRx Corporation. Mr. Thomas began his career with an auditor firm. He currently serves on the Board of Directors for several privately held companies and Chairman of the Finance Committee of The Walker School, a private Pre-K through twelfth grade school. Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntyre School of Commerce with a business degree with a concentration in accounting. Mr. Thomas brings to our Board of Directors a vital understanding and appreciation of the Company’s business and history acquired through his prior service with the Company. Mr. Thomas has a valuable understanding of the role played by the Board of Directors acquired through service on the boards of multiple other companies.

Ann A. Rosar joined DARA in 2007 as Controller and in January 2008, was named Chief Accounting Officer. Ms. Rosar has over twenty years experience in finance with publicly held companies and more than ten years experience regarding regulatory reporting requirements. Prior to joining the Company, Ms. Rosar was the Manager of Financial Reporting and Accounting with Cicero, Inc. (formerly Level 8 Systems), a provider of business integration software, from June 2000 until November 2007, where she was responsible for Securities and Exchange Commission reporting, audits and budget analysis. Prior to that position, she served as Senior Financial Analyst-Business Operations for Nextel Communications. Ms. Rosar has a MBA in Finance from the University of Houston. Her undergraduate degree is from North Carolina State University.